Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

  1. Blum, J.L.
  2. Douglas Laird, A.
  3. Litton, J.K.
  4. Rugo, H.S.
  5. Ettl, J.
  6. Hurvitz, S.A.
  7. Martin, M.
  8. Roché, H.H.
  9. Lee, K.-H.
  10. Goodwin, A.
  11. Chen, Y.
  12. Lanzalone, S.
  13. Chelliserry, J.
  14. Czibere, A.
  15. Hopkins, J.F.
  16. Albacker, L.A.
  17. Mina, L.A.
Aldizkaria:
Clinical Cancer Research

ISSN: 1557-3265,  1078-0432

Argitalpen urtea: 2022

Alea: 28

Zenbakia: 7

Orrialdeak: 1383-1390

Mota: Artikulua

DOI: 10.1158/1078-0432.CCR-21-2080 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus